<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00158743</url>
  </required_header>
  <id_info>
    <org_study_id>DEEP</org_study_id>
    <nct_id>NCT00158743</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Digibind for Treatment of Severe Preeclampsia</brief_title>
  <official_title>A Parallel, Double-blind, Placebo Controlled, Randomized Comparison of an Anti-digoxin Antibody (Digibind) Versus Placebo for the Treatment of Antepartum Patients With Severe Preeclampsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BTG International Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BTG International Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a commercially available anti-digoxin
      antibody, Digibind, can delay delivery in patients with severe pre-eclampsia. If so, this
      would allow more time for maternally administered steroids to prevent the development of
      respiratory complications in premature infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preeclampsia (PE) is a serious complication of third trimester pregnancy manifested by high
      blood pressure, proteinuria, edema, encephalopathy sometimes with seizures, and hepatic
      failure. There is no known specific treatment, although palliative measures such as
      antihypertensive drugs, magnesium, steroids and early delivery improve outcomes. Multiple
      abnormalities have been demonstrated in PE but the relation of these abnormalities to the
      cause, pathophysiology and treatment is unknown. One of these abnormalities is elevation in
      the circulating level of a &quot;digoxin-like&quot; factor (EDLF), an unknown substance that cross
      reacts with digoxin antibodies and inhibits Na,K ATPase. An extensive literature supports the
      hypothesis that increased levels of EDLF may be a causative factor in the pathogenesis of
      hypertension. Increased levels of this factor are found both in maternal and fetal blood,
      both in normal pregnancy, and in pregnancy complicated by PE. Levels of this factor are
      higher in PE than in normal pregnancy suggesting it might play a role in the pathophysiology
      of PE.

      Digibind (Glaxo Smith Kline) is a commercially available FAB fragment, antidigoxin antibody
      approved for the treatment of digoxin intoxication. In experimental models of hypertension
      with elevated EDLF levels, Digibind has been shown to lower blood pressure, suggesting that
      the antibody cross reacts with EDLF. These observations have led to the hypothesis that
      Digibind might ameliorate some of the manifestations of PE, especially the hypertension.
      Based on an extensive pre-clinical literature supporting that hypothesis, and encouraging
      results in 8 cases, a clinical trial is planned to test the effect of Digibind in severe PE.
      The study is a multi- site, parallel, double blind, placebo controlled, randomized trial.
      After randomization, 50 patients will be given the usual treatment for severe PE, plus study
      drug (Digibind or placebo) every six hours, for 48 hours. The study may be terminated during
      the treatment period for standard indications for early delivery.

      Data collection will include: delivery latency, maternal blood pressure, antihypertensive
      use, renal function, hepatic function, CBC and platelet count, and umbilical artery blood
      flow by color doppler. Standard maternal and fetal monitoring will be followed. Newborn
      assessment will include: status at birth, APGAR score, NICU length of stay, respirator use
      and duration, and any medical complications. Adverse events will be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Creatinine Clearance</measure>
    <time_frame>Baseline to 24-48 hours.</time_frame>
    <description>change from baseline in creatinine clearance measured at 24 to 48 hours, comparing patients who received placebo with those who received digoxin immune fab</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Pre-eclampsia</condition>
  <arm_group>
    <arm_group_label>Digoxin immune fab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Digibind treatment plus standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo (sodium chloride)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-digoxin antibody (FAB fragment)</intervention_name>
    <description>intravenous administered, dose based on weight (assuming 4ng/mL EDLF concentration). Dose every 6 hours x 48 hours.</description>
    <arm_group_label>Digoxin immune fab</arm_group_label>
    <other_name>Digibind</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sodium chloride</intervention_name>
    <arm_group_label>placebo (sodium chloride)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A subject with a diagnosis of severe preeclampsia will be eligible for inclusion if
             she meets the following criteria:

               1. In the opinion of the investigator delivery is considered to be probably required
                  within a 72 hour time period and, therefore, corticosteroid administration is
                  needed.

               2. Meets both American College of Obstetricians (ACOG) criteria for preeclampsia
                  (modified to limit selection to patients with the required severity)

                    -  A systolic blood pressure of 140 mm Hg or higher or a diastolic blood
                       pressure of 90 mm Hg or higher occurring after 20 weeks of gestation in a
                       woman whose blood pressure has previously been normal;

                    -  Proteinuria, with excretion of 0.3 g or more of protein in a 24-hour urine
                       specimen or a urine dipstick reading of 1+ or more.

               3. Meets at least one of the following ACOG criteria for severe preeclampsia
                  (modified to limit selection to patients with the required severity)

                  . Proteinuria of 5 grams or higher in a 24-hour specimen or 3+ or greater on 2
                  random urine samples collected at least 4 hours apart

                    -  A systolic blood pressure of 160 mm Hg or higher or a diastolic blood
                       pressure of 110 mm Hg or higher on two occasions six or more hours apart in
                       a pregnant woman who is on bed rest;

                    -  Oliguria, with excretion of less than 500 ml of urine in 24 hours or average
                       of ≤ 25 ml/hour over a 3 hour period;

                    -  Pulmonary edema;

                    -  Impairment of liver function [AST(SGOT) &gt; 72 U/L or ALT(SGPT) &gt; 72 U/L or
                       LDH &gt; 600 U/L or Total Bilirubin &gt;1.2 mg/DL)];

                    -  Visual or cerebral disturbances;

                    -  Decreased platelet count (≥50,000/mm3 and ≤ 100,000/mm3).

               4. Has a fetal gestational age of 23 5/7 to 34 weeks.

        Exclusion Criteria:

          1. Is in need of immediate delivery as soon as clinically appropriate

          2. Eclampsia

          3. Significant antecedent obstetrical problems which may interfere with study assessments
             or safe participation in the study

          4. Evidence of non-reassuring fetal well being

          5. Evidence of lethal fetal anomaly

          6. Antecedent hypertension (hypertension secondary to preeclampsia, treated or untreated
             is allowed)

          7. Antecedent renal, hepatic, or autoimmune disease

          8. Medical or psychiatric disorder which is unstable or which might interfere with study
             assessments or safe participation in the study

          9. Evidence on medical history/evaluation of use of or need for digitalis-like products
             currently or in the future

         10. History of a severe allergic reaction to previous medication, severe asthma, or atopy.
             (Patients with a history of allergic reactions to antibiotics, papain, chymopapain, or
             other papaya extracts may be more susceptible to allergic reactions to Digibind®)

         11. Prior use of antibodies/FAB fragments from sheep (e.g. Digibind®, DigiFab, CroFab)

         12. Serum creatinine ≥ 1.5 mg/dl

         13. Platelet count &lt;50,000/mm3

         14. Patient intends to breast feed and does not agree to wait for a minimum of seven days
             after the last Digibind® dose (a breast pump would be used for this seven day period)

         15. Inability to understand and provide informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vardaman M Buckalew, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Perinatal Associates</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winnie Palmer Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology, Louisiana State University Health Sciences Center, PO Box 33932, 1501 Kings Highway</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Mary's Health Center</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 634, PO Box 250619</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of OB-GYN, Division of Maternal Fetal Medicine, University of Texas Medical Branch, 301 University Boulevard</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0587</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Mark's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Adair CD, Buckalew V, Taylor K, Ernest JM, Frye AH, Evans C, Veille JC. Elevated endoxin-like factor complicating a multifetal second trimester pregnancy: treatment with digoxin-binding immunoglobulin. Am J Nephrol. 1996;16(6):529-31.</citation>
    <PMID>8955766</PMID>
  </reference>
  <reference>
    <citation>Gusdon JP Jr, Buckalew VM Jr, Hennessy JF. A digoxin-like immunoreactive substance in preeclampsia. Am J Obstet Gynecol. 1984 Sep 1;150(1):83-5.</citation>
    <PMID>6540989</PMID>
  </reference>
  <reference>
    <citation>Poston L, Morris JF, Wolfe CD, Hilton PJ. Serum digoxin-like substances in pregnancy-induced hypertension. Clin Sci (Lond). 1989 Aug;77(2):189-94.</citation>
    <PMID>2548800</PMID>
  </reference>
  <reference>
    <citation>Graves SW, Williams GH. An endogenous ouabain-like factor associated with hypertensive pregnant women. J Clin Endocrinol Metab. 1984 Dec;59(6):1070-4.</citation>
    <PMID>6092405</PMID>
  </reference>
  <reference>
    <citation>Lopatin DA, Ailamazian EK, Dmitrieva RI, Shpen VM, Fedorova OV, Doris PA, Bagrov AY. Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia. J Hypertens. 1999 Aug;17(8):1179-87.</citation>
    <PMID>10466474</PMID>
  </reference>
  <reference>
    <citation>Krep H, Price DA, Soszynski P, Tao QF, Graves SW, Hollenberg NK. Volume sensitive hypertension and the digoxin-like factor. Reversal by a Fab directed against digoxin in DOCA-salt hypertensive rats. Am J Hypertens. 1995 Sep;8(9):921-7.</citation>
    <PMID>8541008</PMID>
  </reference>
  <reference>
    <citation>Krep HH, Graves SW, Price DA, Lazarus M, Ensign A, Soszynski PA, Hollenberg NK. Reversal of sodium pump inhibitor induced vascular smooth muscle contraction with digibind. Stoichiometry and its implications. Am J Hypertens. 1996 Jan;9(1):39-46.</citation>
    <PMID>8834705</PMID>
  </reference>
  <reference>
    <citation>Gruber KA, Whitaker JM, Buckalew VM Jr. Endogenous digitalis-like substance in plasma of volume-expanded dogs. Nature. 1980 Oct 23;287(5784):743-5.</citation>
    <PMID>6253813</PMID>
  </reference>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <results_first_submitted>July 17, 2014</results_first_submitted>
  <results_first_submitted_qc>July 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 8, 2014</results_first_posted>
  <last_update_submitted>July 17, 2014</last_update_submitted>
  <last_update_submitted_qc>July 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pre-eclampsia</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Endogenous digitalis-like factor</keyword>
  <keyword>Anti-digoxin antibody</keyword>
  <keyword>Digibind</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulin Fab Fragments</mesh_term>
    <mesh_term>Digoxin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Digoxin Immune Fab</title>
          <description>Digibind treatment plus standard of care
Anti-digoxin antibody (FAB fragment): intravenous administered, dose based on weight (assuming 4ng/mL EDLF concentration). Dose every 6 hours x 48 hours.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>sodium chloride placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Digoxin Immune Fab</title>
          <description>Digibind treatment plus standard of care
Anti-digoxin antibody (FAB fragment): intravenous administered, dose based on weight (assuming 4ng/mL EDLF concentration). Dose every 6 hours x 48 hours.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>sodium chloride placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" spread="7.1"/>
                    <measurement group_id="B2" value="26" spread="6.2"/>
                    <measurement group_id="B3" value="26" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Creatinine Clearance</title>
        <description>change from baseline in creatinine clearance measured at 24 to 48 hours, comparing patients who received placebo with those who received digoxin immune fab</description>
        <time_frame>Baseline to 24-48 hours.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Digoxin Immune Fab</title>
            <description>Digibind treatment plus standard of care
Anti-digoxin antibody (FAB fragment): intravenous administered, dose based on weight (assuming 4ng/mL EDLF concentration). Dose every 6 hours x 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>sodium chloride placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Creatinine Clearance</title>
          <description>change from baseline in creatinine clearance measured at 24 to 48 hours, comparing patients who received placebo with those who received digoxin immune fab</description>
          <units>milliliters/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8" spread="43"/>
                    <measurement group_id="O2" value="-22" spread="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Digoxin Immune Fab</title>
          <description>Digibind treatment plus standard of care
Anti-digoxin antibody (FAB fragment): intravenous administered, dose based on weight (assuming 4ng/mL EDLF concentration). Dose every 6 hours x 48 hours.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>sodium chloride placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>hypothermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>uterine atony</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Suzanne Ward Pharm D</name_or_title>
      <organization>BTG International Inc</organization>
      <phone>610-278-1660</phone>
      <email>suzanne.ward@btgplc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

